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Increased CD 40 ligand expression on platelets is associated with 
increased cardiac events before and after total hip arthroplasty. 
M.Ray1, S. Crawford2, R. Crawford2, D. Walters1.* 
1Cardiology and 2Orthopaedic Program, The Prince Charles Hospital, 
Brisbane ,Qld. 
The aim of this study was to determine if pre-operative levels of CD 
40 Ligand (L) in patients undergoing non cardiac surgery were 
associated with the development of adverse post operative 
cardiovascular events. Methods: Patients undergoing elective 
primary, unilateral cemented total hip arthroplasty (THR) under 
general anaesthesia were consented to participate in the study in 
accordance with the hospital Research and Ethics Committee. A BD 
FACScan flow cytometer with a 488 nm argon-ion laser performed 
3-colour analysis. CD 40L on the platelet surface was measured with 
CD154. An adverse cardiovascular event was defined as death, acute 
myocardial infarction or the onset of a new atrial or ventricular 
arrhythmia. Results:  The study included 45 patients, mean age 69 ± 
10.9 yrs of which 51% were male. In all cases the operation was 
considered a technical success. There were no signs of deep vein 
thrombosis detected by ultrasound 5 days after surgery in all 
patients. Cardiovascular events of ischaemia or atrial fibrillation post 
hip replacement occurred in 6 patients. These consisted of non ST 
elevation myocardial infarction (NSTEMI) plus atrial fibrillation in 
2 patients, atrial fibrillation in 2 patients and NSTEMI and atrial 
fibrillation in 2 patients. CD 40L expression prior to THR was 
associated with the development of adverse post operative adverse 
cardiac events (p< 0.01 CI 0.956-6.597), non ST elevation 
myocardial infarction (p=0.064) and atrial fibrillation (p= 0.043). Six 
weeks after surgery, history and clinical assessment revealed no 
evidence of thrombosis or infection. There was one case of wound 
ooze and haematoma that required washout and resuturing 15 days 
after surgery. 
Conclusion : CD 40L expression may be useful in predicting 
adverse cardiovascular events in patients undergoing non cardiac 
surgery.  
 
 2
Introduction 
 
CD40 ligand (CD40L) is expressed on platelets that have become 
activated 1 and increased levels have been demonstrated on the surface 
of platelets from patients with chronic heart failure 2. Once CD40L has 
been translocated to the platelet surface, it is cleaved to the soluble form 
(sCD40L) which induces an inflammatory response from endothelial cells 
as well as promoting thrombosis 3. 
Cardiac complications after total hip arthroplasty (THA) are significant. 
The mortality rate three months from cardiac events has been reported 
as 0.16%, higher than that from pulmonary embolus (0.11%) 4. 
This study aimed to investigate the association of CD40L expressed on 
the platelets before THA with both the patients’ history of cardiac disease 
and adverse cardiac events after the surgery. 
 
Method  
 
Patient population 
 
A total of 45 patients undergoing primary, unilateral, cemented THA were 
studied. These patients were treated with aprotinin, EACA or placebo as 
described previously in a randomised study to study the effectiveness of 
these two antifibrinolytic agents in the reduction of bleeding 5.  All 
patients consented to participate in the study including having blood 
samples for flow cytometric analysis taken via an arterial line with the 
approval of the hospital Research and Ethics Committee. The study was 
conducted in accordance with the World Medical Association Declaration 
of Helsinki. 
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Patients were excluded if they had a previous history of pulmonary 
embolus, stroke, deep vein thrombosis, transient ischaemic attacks, 
malignancy, or renal failure (creatinine >0.15 mmol/L). 
  
After the surgery all patients received 150 mg of aspirin daily as 
prophylaxis. Below knee thromboembolic stockings (Thrombexin Climax, 
MediBayreuth, Germany) and foot pumps (Impulse, Novamedix, 
Mansfield, UK) were employed. 
 
Blood sampling 
 
Two samples were taken, one before the administration of any study 
drug and the second one hour after the end of surgery. 2.7 mL of blood 
was added to a Vacutainer tubes (Becton Dickinson, NJ, USA) 
containing 0.109 M buffered trisodium citrate and immediately stained 
and tested by flow cytometry. 
 
Flow cytometry analysis 
This analysis was performed using a BD FACScan flow cytometer with a 
488 nm argon-ion laser.  Platelets were selected by forward scatter and 
side scatter as well as by positive staining with CD42a (BD Biosciences 
(BD) (San Jose, California, USA)) that targets GP IX and GP 1b-IX-V 
that are common to all platelets. CD40 ligand on the platelet surface was 
measured with CD154 (BD) 6. A matched isotype was used as a 
negative control. The CELLQuest program was used to analyse the data. 
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Quality control of the flow cytometer was ensured throughout the study 
by using CaliBRITE 3 beads (BD). 
 
Adverse Cardiac Events 
The cardiologist was blinded to all aspects of the study patients and 
assessed the patients’ charts after their discharge. An adverse event 
was defined as two of the three events of chest pain, ECG changes and 
elevation of troponin I. 
 
Results 
 
Demographics 
Three of the 15 patients who received aprotinin, 3 of the 15 who received 
EACA and none of the placebo group experienced adverse 
postoperative cardiac events. There was no statistically significant 
relationship between the administration of aprotinin or EACA and the 
occurrence of postoperative cardiac events.  
 
The other demographics describing the patient population are shown in 
Table 1. Patients with adverse postoperative cardiac events were more 
commonly diabetic and stayed in hospital longer. 
 
 
 
Table 1. Demographics of patients. 
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 Postoperative 
cardiac events 
No postoperative 
cardiac events 
n 6 39 
History of cardiac events 3 6 
Hypertension 1 13 
Diabetes 2  # 1 
Recent history Viox 2 6 
Male:female 2:4 21:18 
Age (years) 74 71 
Hospital stay (days) 11.5  # 7.0 
Preoperative haemoglobin (g/L) 133 132 
Preoperative platelet count (x109/L) 303 275 
Preoperative platelet aggregation (ohm) 4.5 5.0 
 
Values represent number or median value 
# p = <0.05 
 
 
CD40 ligand expression on platelets 
 
Antifibrinolytic therapy had no effect on platelet activation in this group of 
patients 5. Before or after THA there was no difference in CD40L 
expression on platelets between the aprotinin, EACA or placebo groups, 
so the results of all patients were considered together. 
CD40L expression was markedly decreased during THA surgery (Fig. 1).   
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Fig. 1 The expression of CD40L on patients’ platelets before and one hour 
after the completion of THA. The horizontal bar represents the median value, 
the box the 25th and 75th quartiles and the whiskers the range of values.   
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